Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
September 9, 2021 12:35 PM EDTUpdated September 10, 02:47 PM
Pharma

Bio­gen CEO Vounatsos laments 'con­fu­sion' and 'mis­in­for­ma­tion' lead­ing to chal­lenges with Aduhelm up­take

Zachary Brennan

Senior Editor

Bio­gen CEO Michel Vounatsos on Thurs­day ad­mit­ted the com­pa­ny is ex­pe­ri­enc­ing some “near term chal­lenges” in launch­ing its con­tro­ver­sial new Alzheimer’s drug, a lit­tle more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times